

TERMINATIONS OF LICENSES ISSUED:

Location of Use/Possession of Material	Name of Licensed Entity	License Number	City of Licensed Entity	Amendment Number	Date of Action
San Antonio	Schnitzler Cardiovascular Consultants	L05792	San Antonio	15	10/09/18
Throughout TX	Emergency Environmental Services L.L.C.	L06810	Haslet	01	10/01/18
Throughout TX	Sunset Well Service Inc.	L06426	Midland	05	10/01/18
Webster	Bay Area Regional Medical Center L.L.C.	L06655	Webster	12	10/02/18

TRD-201804722
 Barbara L. Klein
 General Counsel
 Department of State Health Services
 Filed: October 31, 2018

Barbara L. Klein
 General Counsel
 Department of State Health Services
 Filed: October 31, 2018



Texas Department of Insurance

Company Licensing

Application for ZALE LIFE INSURANCE COMPANY, a foreign life, accident and/or health company, to change its name to LANGHORNE REINSURANCE (ARIZONA) LTD. The home office is in Scottsdale, Arizona.

Application for SAN FRANCISCO REINSURANCE COMPANY, a foreign fire and/or casualty company, to change its name to ALLIANZ REINSURANCE AMERICA, INC. The home office is in Petaluma, California.

Any objections must be filed with the Texas Department of Insurance, within twenty (20) calendar days from the date of the *Texas Register* publication, addressed to the attention of Jeff Hunt, 333 Guadalupe Street, MC 103-CL, Austin, Texas 78701.

TRD-201804720
 Norma Garcia
 General Counsel
 Texas Department of Insurance
 Filed: October 31, 2018



Texas Department of Insurance, Division of Workers' Compensation

Correction of Error

The Texas Department of Insurance, Division of Workers' Compensation submitted proposed amendments to Chapter 116, General Provisions - Subsequent Injury Fund, §116.11, which are published in the proposed rules section of the November 2, 2018, issue of the *Texas Register* (43 TexReg 7312). Due to publication errors made by the *Texas Register*, an incomplete list of the statutory authority for the proposed amendments appeared in the preamble.

On page 7313, second column, the sentence beginning "Amended §116.11 . . ." should read as follows:

Amended §116.11 is proposed under the authority of Labor Code §§402.00111, 402.00116, 402.00128, and 402.061.

TRD-201804714



Correction of Error

Order Placing Certain Food and Drug Administration Approved Drugs Containing Cannabidiol into Schedule V

The Acting Administrator of the Drug Enforcement Administration issued a final order placing Food and Drug Administration approved drugs that contain cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols into Schedule V, effective September 28, 2018. This final order was published in the *Federal Register*, Volume 83, Number 189, pages 48950 - 48953. This action was based on the following:

1. FDA approved drugs containing cannabidiol have currently accepted medical use in treatment in the United States;
2. FDA approved drugs containing cannabidiol no longer meet the criteria for placement in Schedule I;
3. FDA approved drugs containing cannabidiol have a very low potential for abuse; and,
4. The amendment was necessary to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced action was published in the *Federal Register*. In the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that FDA-approved drug products containing cannabidiol with no more than 0.1 percent residual tetrahydrocannabinols be placed into Schedule V. Due to the fact that this safe and effective drug is now available through federal Food and Drug Administration approval, immediately scheduling this drug will mitigate imminent hazard to public safety by offering access to an approved therapy that will address potentially life-threatening situations for a known population of children with intractable epilepsy.

SCHEDULE V

*Approved cannabidiol drugs.

A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1 -yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.

Changes to the schedules are marked with an asterisk(*).

TRD-201804732